My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC   - Episode 2

Extended Follow Up of KEYNOTE-B61

,

Martin H. Voss, MD, provides an update on the extended follow-up data from the phase 2 KEYNOTE-B61 study, which investigates the efficacy and safety of combination therapy consisting of pembrolizumab and lenvatinib as a first-line treatment option for patients with advanced non-clear cell renal cell carcinoma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Evolving Treatment Standards in Non-Clear Cell RCC
    Now Viewing
    EP. 2: Extended Follow Up of KEYNOTE-B61
    EP. 3: Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC
    EP. 4: STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC
    EP. 5: Case Presentation: 61-year-old male Renal Cell Carcinoma
    EP. 6: Use of Combination Regimens in Frontline RCC
    EP. 7: Treatment Decision Making in first-line combinations for advanced RCC
    EP. 8: AE Management for Combination Regimens in Advanced RCC
    EP. 9: AE Management for Combination Regimens in Advanced RCC
    EP. 10: Optimizing Treatment in Advanced RCC
    EP. 11: Dr Albiges Discusses a Non-Clear Cell RCC Patient Profile
    EP. 12: Updates in the Treatment Approach for Non-clear cell RCC
    EP. 13: Dr Albiges Reviews Long term follow up data from KEYNOTE-B61
    EP. 14: Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC
    EP. 15: Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)
    EP. 16: Summary and Forward Looking for RCC
    1. Please discuss extended follow up from the phase 2 KEYNOTE-B61 study investigating pembrolizumab + lenvatinib in the first-line treatment of advanced non-clear cell RCC. (Voss M et al. ASCO GU 2024, Abstract #2)
    2. Please provide a brief background surrounding KEYNOTE-B61 (Albiges, et al. Lancet Oncol, 2023)
    3. How did the response rates compare across histologies?
    4. Considering the observed OS benefit with adjuvant pembro, do you intend to approach its adjuvant use in a similar or different manner in this treatment setting?
    x